VolitionRx (VNRX) insider: 18,341 RSUs settled, shares retained for tax
Rhea-AI Filing Summary
Transaction summary: Ann-Louise Batchelor, Group Chief Marketing Officer, filed a Form 4 for VolitionRx Ltd (VNRX) reporting activity dated 08/01/2025.
Details: The filing states 18,341 restricted stock units were settled in lieu of cash compensation and that 8,620 shares were retained by VolitionRx for cancellation to satisfy the reporting person’s tax withholding obligations. The filing explicitly states no shares were sold. Following the reported transaction, Batchelor beneficially owns 132,486 shares directly and 29,406 shares indirectly (by spouse). The table shows a price of $0.64. Form signed 08/05/2025.
Positive
- None.
Negative
- None.
Insights
TL;DR: Routine RSU settlement used for tax withholding; no sale reported and limited investor impact.
The Form 4 documents settlement of 18,341 RSUs with 8,620 shares retained for tax withholding. The company retained and cancelled shares to meet withholding obligations, and the filer did not sell shares. Post-transaction beneficial ownership is 132,486 direct and 29,406 indirect. This is a compensatory equity event and, per the filing, not a market disposition, so it is unlikely to materially affect valuation or liquidity in the absence of other disclosures.
TL;DR: Disclosure appears compliant; transaction reflects standard tax-withholding mechanics on RSU settlement.
The filing identifies the reporting person, relationship (Group Chief Marketing Officer), transaction date (08/01/2025) and explains the retained shares were cancelled by VolitionRx to satisfy tax withholding. The Form 4 is signed and dated 08/05/2025. From a governance and compliance perspective, the document contains the required explanatory note and shows no indicia of an unscheduled sale or other compensatory irregularity.